Want to see BYSI full AI Analyst Report?
Top Page
Beyondspring
(NASDAQ:BYSI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.79
▲(19.55% Upside)
Action:Reiterated
Date:10/02/26
The score is primarily held down by weak financial performance (minimal revenue, ongoing cash burn, and negative equity). Technicals are neutral-to-weak with the stock still below longer-term averages, while valuation is constrained by negative earnings and no dividend. Corporate events add material listing-risk overhang, partly mitigated by actions to improve funding flexibility and capital efficiency.
Positive Factors
Trial funding efficiency
The China collaboration can materially improve capital efficiency by shifting funding and execution of a large trial segment to a partner. Retaining rights outside Greater China and access to China-generated data may support global development while reducing near-term internal cash demands.
Negative Factors
No recurring product revenue
With revenue effectively absent, BeyondSpring has no established product sales base to offset research, clinical, regulatory, and corporate costs. Earnings visibility therefore remains dependent on development outcomes and potential future partnerships rather than recurring operating income.
Read all positive and negative factors
Positive Factors
Negative Factors
Trial funding efficiency
The China collaboration can materially improve capital efficiency by shifting funding and execution of a large trial segment to a partner. Retaining rights outside Greater China and access to China-generated data may support global development while reducing near-term internal cash demands.
Read all positive factors
Beyondspring (BYSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.37M
Dividend YieldN/A
Average Volume (3M)434.27K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,119,820
10 Day Avg. Volume1,109,792
30 Day Avg. Volume434,267
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.71K
Enterprise Value/Ebitda-8.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Beyondspring Business Overview & Revenue Model
Company Description
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced th...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Beyondspring has historically not relied on recurring product sales as its primary source of revenue because its key product candidates (including plinabulin) have been in development and subject to c...
Beyondspring Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.35M | 1.35M |
| Gross Profit | -38.00K | -87.00K | 0.00 | -302.00K | 1.35M | 1.35M |
| EBITDA | -7.87M | -8.54M | -8.48M | -13.62M | -34.96M | -64.49M |
| Net Income | -6.68M | -7.99M | -11.12M | -21.03M | -33.28M | -64.18M |
Balance Sheet | ||||||
| Total Assets | 14.61M | 25.93M | 34.31M | 24.81M | 46.22M | 81.65M |
| Cash, Cash Equivalents and Short-Term Investments | 6.53M | 12.56M | 2.92M | 15.34M | 37.27M | 72.37M |
| Total Debt | 171.00K | 320.00K | 589.00K | 847.00K | 4.96M | 3.58M |
| Total Liabilities | 50.63M | 49.92M | 48.60M | 48.27M | 49.23M | 60.73M |
| Stockholders Equity | -35.57M | -32.16M | -32.90M | -26.80M | -5.98M | 26.68M |
Cash Flow | ||||||
| Free Cash Flow | -17.05M | -20.07M | -16.67M | -16.57M | -28.18M | -50.09M |
| Operating Cash Flow | -17.05M | -20.02M | -16.44M | -16.47M | -28.15M | -47.24M |
| Investing Cash Flow | 1.26M | 13.48M | -12.01M | -100.00K | 18.25M | -20.41M |
| Financing Cash Flow | -2.24M | 2.27M | 26.79M | 4.00K | 3.43M | 1.00K |
Beyondspring Technical Analysis
Negative
0.66
Price Trends
0.81
Negative
1.18
Negative
1.39
Negative
Market Momentum
<0.01
Negative
50.35
Neutral
38.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.81, and below the 200-day MA of 1.39, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 38.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BYSI.
Beyondspring Risk Analysis
Beyondspring disclosed 87 risk factors in its most recent earnings report. Beyondspring reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beyondspring Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $74.63M | -3.42 | -161.58% | ― | ― | 23.02% | |
48 Neutral | $280.59M | -2.36 | -63.05% | ― | -51.65% | 91.93% | |
47 Neutral | $292.88M | -4.65 | -75.35% | ― | 220.34% | 55.73% | |
44 Neutral | $32.37M | -4.77 | 19.96% | ― | ― | ― | |
42 Neutral | $26.96M | -3.42 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
BYSI
Beyondspring
0.79
-0.99
-55.79%
XFOR
X4 Pharmaceuticals
2.83
-0.54
-16.02%
ABVC
ABVC BioPharma
1.01
-2.12
-67.73%
PRLD
Prelude Therapeutics
3.67
2.21
151.37%
GANX
Gain Therapeutics
1.71
-0.51
-22.97%
Beyondspring Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
BeyondSpring Faces Nasdaq Listing Compliance Risk
Negative
Oct 2, 2026
On September 29, 2026, BeyondSpring Inc. disclosed that Nasdaq notified the company its market value of listed securities had fallen below the $35 million minimum for 30 straight business days, breaching the Capital Market’s continued listin...
Business Operations and StrategyPrivate Placements and Financing
BeyondSpring launches ATM program to bolster financing
Positive
Sep 29, 2026
On September 28 and 29, 2026, BeyondSpring entered into a share purchase and strategic collaboration with Biolin Investment and its Chinese subsidiary Bulin, and launched an at-the-market equity program. Under the collaboration, BeyondSpring will ...
Delistings and Listing ChangesRegulatory Filings and Compliance
BeyondSpring Faces Nasdaq Noncompliance Over Minimum Bid Price
Negative
Sep 18, 2026
On September 17, 2026, BeyondSpring Inc. received notice from Nasdaq that its ordinary shares had traded below the $1.00 minimum bid price for 30 consecutive business days, placing the company out of compliance with Nasdaq’s continued listin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.